PENTA Publications

Home / current

Trials

Treatment Guidelines

PENTA Network

Training

Publications

Key publications

      PENTA 1
      PENTA 3
      PENTA 4
      PENTA 5
      PENTA 7
      PENTA 8
      PENPACT1
      PENTA 11
      PENTA 13
      PENTA 15
      General PENTA Publications
      Immunology
      Resistance
      Pharmacology

Publication policy

Other activities
Contacts
Risk calculator
Links
Area for PENTA network members (password needed)

PENTA 1

Writing Committee: Gibb DM, Newberry A, De Rossi A, Kaye S, Loveday C, Muñoz-Fernandez, Rouzioux C, Debré M, Giaquinto C, Babiker A. HIV-1 Viral Load and CD4 Count in Untreated Children with Vertically Acquired Mild or Asymptomatic Disease - PENTA I Virology. AIDS 1998; 12 F1-F8. (Reference)

Writing Committee: Gibb DM, Giacomet V, Livingstone S, McGee L, Harper L, Formica K. Parents' attitudes to their HIV infected children being enrolled into a placebo controlled trial- the PENTA I trial. HIV Medicine 1999; 1: 25-31. (Reference)

Writing Committee (alphabetical) Aboulker.J.P, Babiker. A., Darbyshire. J.H., Debre. M., Giaquinto.C., Gibb.D.M., Harper L., Newberry. A., Saidi.Y. Five-year follow-up of vertically HIV-infected children in a randomised double blind controlled trial of immediate versus deferred zidovudine: the PENTA 1 trial. Arch Dis Child 2001; 84: 230-236. (.pdf file)

PENTA 3

Gibb DM, Carrière I, Giaquinto C, Martinez M for PENTA. The Safety and Tolerability of Zidovudine (ZDV) and Zalcitabine (ddC) in Children with Symptomatic HIV Infection - PENTA 3 (Abstract). VIth European Conference on Clinical Aspects and Treatment of HIV-Infection, Hamburg, Germany 1-15 October, 1997.

PENTA 3 Trial. Report to Roche, Oct 1997

PENTA 4

Writing Committee (alphabetical): Aboulker JP, Babiker A, Carrière I, Darbyshire JH Debré M, Giaquinto C, Gibb DM, Harper L, Newberry A, Saidi Y, Tudor-Williams G. A randomised double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. AIDS 1998; 12 F151-F160. (Reference)

Kaye S, Loveday C, Gibb DM., Newberry A. Plasma viral load and genotypic resistance patterns in children adding lamivudine to current reverse transcriptase inhibitor therapy (PENTA 4 Trial). IVth International Congress Glasgow, 8-12 November 1998. Abstract P305

PENTA 5

King D, Gibb DM, Gotch F, Larsson-Sciard E. Reconstitution of the T-cell Pool in Treated, HIV-infected Children. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30- February 2, 2000. Abstract 322.

King DJ, Gotch FM, Larsson-Sciard EL; Paediatric European Network for Treatment of AIDS (PENTA). T-cell re-population in HIV-infected children on highly active anti-retroviral therapy (HAART). Clin Exp Immunol. 2001 Sep;125(3):447-54. (Reference)

Gibb DM, Newberry A, Klein N, de Rossi A, Grosch-Wörner I, Babiker A. Immune repopulation after HAART in previously untreated HIV-1 infected children. The Lancet 2000; 355: 1331-2. (Reference)

Gibb. D. M. for the PENTA 5 Executive and the PENTA Steering Committee. A randomised trial evaluating three NRTI regimens with and without Nelfinavir in HIV-infected children: 48 week follow-up from the PENTA 5 trial. Oral presentation at 5th International Congress on Drug Therapy in HIV Infection, Glasgow 22-26 October 2000 also published in AIDS 2000, Vol 14, supp4 p.58 (abstractPL6.8)

Kaye S. on behalf of the PENTA Virology Committee. Drug resistance in a trial of nucleoside analogue and protease inhibitor therapy in children (PENTA 5). 5th International Congress on Drug Therapy in HIV Infection, Glasgow 22-26 October 2000. Poster 308.

Loveday. C., Walker. A.S., Gibb. D.M., on behalf of the PENTA virology Group. Evolution of drug resistance in antiretroviral therapy-naïve children in PENTA 5. Fifth International Workshop on HIV Drug Resistance and Treatment Strategies, 2001, Scottsdale, USA (abstract 109), Antiviral Therapy 2001, Vol 6 (supplement 1) : 82

King D J.S., Gotch F M., Larsson-Sciard E. T cell repopulation in HIV infected children on highly active anti-retroviral therapy (HAART). Clinical and Experimental Immunology 2001, vol 125, no. 3 pp. 447-454.

Pillay D, Gibb DM, Walker AS, De Rossi A, Kaye S, Ait-Khaled M, Muñoz-Fernandez M, Babiker A for the PENTA Group. The Impact of HIV-1 Subtypes on Virological Response and Emergence of Resistance in the PENTA 5 Trial. 9th Conference on Retroviruses and Opportunistic Infections February 24-28, 2002 - Seattle. Poster 813-W (.pdf file)

De Rossi A, Klein N, Walker AS, De Forni D, Babiker A, King D, Gibb DM for the PENTA Group. TREC Response to Antiretroviral Therapy in HIV-infected Children in the PENTA 5 Trial 9th Conference on Retroviruses and Opportunistic Infections February 24-28, 2002 - Seattle. Poster 807-W. (.pdf file)

Writing Committee (alphabetical): Aboulker J-P, Babiker A, Compagnucci A, Darbyshire JH, Debré M, Giaquinto C, Gibb DM, Harper L, Saidi Y, Walker AS. A Randomised Trial to Compare Dual Nucleoside-Analogue Reverse Transcriptase Inhibitor Regimens (ZDV+3TC or ZDV+ABC or 3TC+ABC) With and Without a Protease Inhibitor (Nelfinavir) in Previously Untreated HIV-infected Children: The PENTA 5 Trial The Lancet 2002; 359: 733-740. (.pdf file)

Gibb DM, Walker AS, Giaquinto C, Harper L, Compagnucci A, Saidi Y, Aboulker JP, Babiker A, Debré M, Darbyshire JH on behalf of the PENTA 5 Steering Committee. 96 week follow-up of the PENTA 5 trial; comparing ZDV+3TC, ZDV+ABC and 3TC+ABC with or without NFV in ART naive children XIV World AIDS Conference, Barcelona, Spain, 7-12 July 2002. Poster TuPpB2051) (.pdf file)

Giacomet V, Gibb DM, Goodall R, McGee L, Walker AS, Giaquinto C. Adherence to HAART in children: results from a questionnaire study of children in PENTA 5 trial. XIV World AIDS Conference, Barcelona, Spain, 7-12 July 2002. Poster TuPpB2050 (.pdf file)

De Rossi A, Walker AS, Klein N, De Forni D, King D, Gibb DM. Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial. J Infect Dis 2002; 186:312-20 (.pdf file)*

Gibb DM, Walker AS, Kaye S, De Rossi A, Ait-Khaled M, Pillay D, Muñoz-Fernandez M, Loveday C, Compagnucci A, Dunn DT, Babiker A. Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral naïve HIV-1 infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial). Antivir Ther 2002; 7(4): 293-303 (.pdf file)

Pillay D, Walker AS, Gibb DM, De Rossi A, Kaye S, Ait-Khaled M, Muñoz-Fernandez M, Babiker A. for the PENTA Steering Committee. Impact of HIV-1 subtypes on virologic response and emergence of drug resistance. J Infect Dis 2002; 186: 617-25 (.pdf file)*

De Rossi A, Walker AS, De Forni D, Gibb DM for PENTA. Biphasic decay of cell-associated HIV-1 DNA in HIV-1 infected children on antiretroviral therapy. Research Letter in AIDS 2002; 16:1961-63 (Reference)

Ait-Khaled M, Lanier R, Richards N, Stone C, Griffin P, Gibb DM, Walker AS, Craig C, Loeliger E, Tisdale M. Zidovudine (ZDV) appears to prevent selection of K65R and L74V, mutations normally selected by Abacavir (ABC) mono- or combination therapies not containing ZDV. 2002 International Meeting of the Institute of Human Virology, September 9-13, 2002, Baltimore (Poster)

Gibb DM, Goodall RL, Giacomet V, McGee L, Compagnucci A, Lyall H for PENTA. Adherence to Prescribed Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Children in the PENTA 5 Trial. Pediatr Inf Dis J 2003; 22 (1): 56-62 (Reference)

De Rossi A, Walker AS, De Forni D, Gibb DM on behalf of PENTA. Relationship between Cell-Associated HIV-1 DNA and Thymic Output in HIV-1 infected Children Initiating Antiretroviral Therapy in the PENTA 5 Trial. 10th Conference on Retroviruses and Opportunistic Infections February 10th - 14th, 2003 - Boston. Poster P-17 (.pdf file)

Gibb DM, Giaquinto C, Walker AS, Harper L, Compagnucci A, Saidi Y, Moulinier C, Aboulker JP, Babiker AG, Debré M, Darbyshire JH on behalf of the PENTA 5 Executive Committee. Three year follow-up of the PENTA 5 trial. 10th Conference on Retroviruses and Opportunistic Infections February 10th - 14th, 2003 - Boston. Poster G1-12 (.pdf file)

Burger DM, Bergshoeff A, de Groot R, Gibb DM, Walker AS, Tréluyer JM, Hoetelmans R, on behalf of the PENTA 5 study group. Maintaining the nelfinavir trough concentration above 0.8 mg/L significantly improves virological response in HIV-1-infected children. J Paediatr 2004; 145(3): 403-405. (.pdf file)

Lanier ER, Givens N, Stone C, Griffin P, Gibb DM, Walker AS, Tisdale M, Irlbeck D, Underwood M, St Clair M and Ait-Khaled M. Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens. HIV Medicine 2004; 5: 394-399. (.pdf file)

De Rossi A, Walker AS, De Forni D, Klein N, Dibb DM for PENTA. Relationship between changes in thymic emigrants and cell-associated HIV-1 DNA in HIV-1 infected children initiating antiretroviral therapy. Antivir Ther. 2005;10(1):63-71.(.pdf file)

Gibb DM, Green H, Saidi Y, Pillay D, Compagnucci A, Harper L, Walker AS, Castelli-Gattinara G, Della Negra M, Levy J, Candeias F, Butler K, Feiterna-Sperling C, Wintergerst U, Giaquinto C on behalf of PENTA 5. 3TC+ABC maintains virological superiority over ZDV+3TC and ZDV+ABC beyond 5 years in children: the PENTA 5 trial. AIDS 2007; 21:947-955 (Reference)

PENTA 7

Litalien C. Giaquinto C. Faye A. Mechinaud F. Grosch I. Compagnucci A. Jacqz-Aigrain E. Nelfinavir doses should be increased in infants less than 3 months. XIII International AIDS Conference, Durban, South Africa, 9-14 July 2000. Abstract Mo PEB 2213 (Reference)

Faye A , Compagnucci A., Saidi Y. for the PENTA 7 Executive Committee. Evaluation of Toxicity, Tolerability and Antiviral Activity of Early d4T+ddI+Nelfinavir (NFV) Therapy in HIV-1 Vertically Infected Infants : 24 Week Preliminary Results from the PENTA 7 Study. 8th Conference on Retroviruses and Opportunistic Infections, Chicago 4-8 February 2001 Poster 678 (Reference)

Litalien C, Faye A, Compagnucci A, Jacqz-Aigrain E. Pharmacokinetics (PK) of Nelfinavir (NFV) and its Active Metabolite (M8) in Very Young Infants Infected with Human Immunodeficiency Virus (HIV). Pediatric Academic Societies 2001 Annual Meeting, April 28 - May 1 2001, Baltimore MD. Abstract 2609.

Compagnucci A, Saidi Y, Chaix ML, Rouzioux C, Gibb DM, Giaquinto C, Debré M, Grosch-Wörner I, Ramos Amador JT, Faye A for the PENTA 7 Executive Committee. Difficulties in achieving suppression of viral replication in vertically HIV-1 infected infants early treated with d4T+ddI+NFV : The PENTA 7 Study. 9th Conference on Retroviruses and Opportunistic Infections February 24-28, 2002 - Seattle. Poster 809 – W. (.pdf file)

Litalien C, Faye A, Compagnucci A, Giaquinto C, Harper L, Gibb DM, Jacqz-Aigrain E for PENTA. Pharmacokinetics of Nelfinavir and its Active Metabolite, hydroxy-tert-butylamide, in Infants Perinatally Infected with HIV-1. Pediatr Inf Dis J 2003; 22(1):48-55 (Reference)

Compagnucci A, Saidi Y, Faye A, Ciria Calavia L, Gibb DM, Girard S, Quernin MH, Harper L, Giaquinto G, Debré M, Weigel R, Giacomet V, Aboulker JA, Jacqz-Aigrain EWalker AS. Impact of NFV and its active metabolite M8 trough levels on virologic response from primary HIV-1 vertically infected children treated with d4T, ddI and NFV in the PENTA 7 study. 2nd IAS Conference on HIV Pathogenesis and Treatment, 13-16 July Paris. Poster 1095 (.pdf file)

Writing Committee (alphabetical): Aboulker J-P, Babiker A, Chaix ML, Compagnucci A, Darbyshire JH, Debré M, Faye A, Giaquinto C, Gibb DM, Harper L, Saidi Y, Walker AS. 72-week follow-up of HAART started in infants aged less than 3 months: CD4, viral load and drug resistance outcomes in the PENTA 7 study. AIDS 2004; 18 (2):237-245 (Reference)

Compagnucci A, Saïdi Y, Harper L, Navarro ML, Girard S, Walker AS, Debré M, Gibb DM, Rampon O, Lachassine E, Schmitz T, Giaquinto C, Aboulker JP, Faye A for the PENTA Steering Committee. Three year outcomes in children treated with HAART before 3 months of age in the PENTA 7 trial. XV International AIDS Conference, 11-16 July 2004, Bangkok. Abstract B11956. (.pdf file)

Compagnucci A, Saïdi Y, Gibb DM, Rampon O, Ramos Amador JT, Feiterna Sperling C, Reliquet V, Giaquinto C, Navarro ML, Girard S, Harper L, Burger D, Treluyer JM, Aboulker JP, Jacqz-Aigrain E and Faye A on behalf of the PENTA 7 Study group. Lower scores of Nelfinavir metabolite M8 were associated with virological failure vertically infected children in the PENTA 7study. 3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005, Rio de Janerio. Abstract MoPe9.2C15 (.pdf file)

Compagnucci A, Saïdi Y, Harper L, Blanche S, Gabiano C, de José Gomez I, Notheis G, Gibb DM, Giaquinto C and Faye A for the PENTA 7 committees. Does Early Treatment Provide Long Term Benefit in HIV-1 Infected Infants? Five Year Outcomes in Children Treated Before 3 Months of Age in the PENTA 7 Trial. 14th Conference on Retroviruses and Opportunistic Infections, 25th-28th February 2007, Los Angeles. Poster 722 Abstract R -151 (.pdf file)

PENTA 8

Giaquinto C, Green H, De Rossi A, Saïdi Y, Compagnucci A, Girard S, Castelli-Gattinara G, della Negra M, Pinto J, De Souza Marques HH, Lyall EGH and Gibb DM on behalf of the PENTA 8 study group. A randomised trial of resistance testing versus no resistance testing in children with virological failure: the PERA (PENTA 8) trial. 3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005, Rio de Janerio. Oral and poster presentation WeOa0106 (.pdf file)

Aboulker J-P, Babiker A, Bacheler L, Burger D, Castelli-Gattinara G, Compagnucci A, Debré M, Della Negra M, Dunn DT, Giacomet V, Giaquinto C, Gibb DM, Green H, Harper L, Lyall H, Pillay D, de Rossi A, Rosso R, Saïdi Y, Walker AS on behalf of the PENTA 8 study group. A randomised controlled trial of genotypic HIV drug resistance testing in HIV-1 infected children: the PERA (PENTA 8) Trial. Antiviral Therapy 2006: 11:857-867 (.pdf file)

PENPACT 1

PENTA and IMPAACT: A phase II/III randomised, open-label trial of combination antiretroviral regimens and treatment-switching strategies in HIV-1-infected antiretroviral naïve children. XVIII International AIDS Conference, 22nd July 2010, Vienna Austria. Presentation.

Gibb DM, Melvin A, Compagnucci A, McKinney R, Tudor-Williams G, Walker AS, Harper L, Hodge J, Powell C, Green H, Saidi Y, Ortiz AA, Toye M, Girard S, Mofenson L, Giaquinto C, Hughes M on behalf of the PENPACT 1 Trial. Choice of first-line ART regimen in PENPACT 1: a randomized trial of combination antiretroviral regimens and treatment switching strategies in antiretroviral naive children >30 days and <18 years of age. XV International AIDS Conference, 11-16 July 2004, Bangkok. Poster TuPeB4442. (.pdf file)

PENTA 11

Lallemant M, Burger D, Lyall H, Buck L, Compagnucci A, Ramos Amador J.T, Mellado Pena M, Fregonese F, Campbell S, Rampon O, Castelli-Gattinara G, Cressey, Khoo S, Tréluyer J.-M, Green H, Saidi Y, Nadal D, Giaquinto C, Gibb D.M on behalf of the PENTA 11 study group. Pharmacokinetic and virological evaluations after stopping NNRTIs in children: a substudy of the PENTA 11 (TICCH) trial. XVI International AIDS Conference, Toronto, 13-18 August 2006. Poster MOPE0206 (.pdf file)

Cressey TR, Green H, Khoo S, Treluyer J-M, Compagnucci A, Saidi Y, Lallement M, Gibb DM, Burger D. Plasma drug concentrations and virologic evaluations after stopping non-nucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1 infected children. Clin Infect Dis. 2008 May 15;46(10):1601-8 (Reference)

Gibb DM, Compagnucci A, Green H, Lallemant M, Saidi Y, Ngo-Giang-Huong N, Taylor C, Mofenson L, Monpoux F, Tomé MIG, Marczyñska M, Nadal D, Wintergerst U, Kanjavanit S, Lyall H, Giaquinto C, Moye J. Treatment interruption in children with chronic HIV-infection: the results of the paediatric European network for treatment of AIDS (PENTA) 11 trial. Journal of the International AIDS Society 2008, 11(Suppl 1):O21 (10 November 2008). (Abstract) (Accompanying poster)

Harrison L, Hamadache D, Bunupuradah T, Mazza A, Ramos Amador JT, Flynn J, Rampon O, Mellado Pena MJ, Floret D, Marczynska M, Puga A, Farrelly L, Riault Y, Lallemant M, Compagnucci A on behalf of the PENTA Trial Steering Committee. Adherence to ART and acceptability of planned treatment interruptions (PTI) in the PENTA 11 trial. 1st International Workshop on HIV Pediatrics, 17 – 18 July 2009, Cape Town, South Africa. (Poster P_90). 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town 19-22 July 2009 ( e-poster CDB106)

PENTA. Response to Planned Treatment Interruptions in HIV-infection varies across Childhood in the PENTA 11 Trial. AIDS. 2010 Jan 16;24(2):231-41 (reference)

Sefe D, Klein N, Mosconi I, Ricci E, Castro, H (nee Green), Jacobsen M, Bernardi S, Pillay D, Gibb DM, and De Rossi A, on behalf of the PENTA Steering Committee. Immunologic and viral dynamics among HIV-infected children after planned treatment interruption: a substudy of the Paediatric European Network for Treatment of AIDS (PENTA) 11 trial. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, 16-19 February 2010, Poster (pdf file)

UNAIDS. Response to Planned Treatment Interruptions in HIV-infection varies across Childhood - Comment in UNAIDS e-newsletter UNAIDS HIV This Week 78, 15 Feb 2010 (pdf file)

PENTA 13

Bergshoeff A, Burger D, Verweij C, Farrelly L, Flynn J, LeProvost M, Walker AS, Novelli V, Lyall H, Gibb DM. Pharmacokinetics (PK) of once daily versus twice daily Lamivudine and Abacavir in HIV-1 infected children: PENTA 13. 11th Conference of Retroviruses and Opportunistic Infections, San Francisco, 8-11 February 2004. Poster 934. (.pdf file)

Bergshoeff A, Burger D, Verweij C, Farrelly L, Flynn J, LeProvost M, Walker AS, Novelli V, Lyall H, Khoo S, Gibb DM on behalf of the PENTA 13 study group. Pharmacokinetics of once versus twice daily lamivudine and abacavir. Simplification of combination treatment in HIV-1 infected children (Penta 13). Antivir Ther. 2005; 10:239-246. (.pdf file)

LeProvost M, Green H, Flynn J, Head S, Clapson M, Lyall H, Novelli V, Farrelly L, Walker AS, Burger DM, Gibb DM on behalf of the PENTA 13 study group. Adherence and acceptability of once daily lamivudine and abacavir in HIV-1 infected children. 3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005, Rio de Janerio. Poster MoPe9.2C03 (.pdf file)

Cella M, Gorter de Vries F, Burger D, Danhof M, Della Pasqua O. A Model-based approach to dose selection in early pediatric development. Clinical Pharmacology and Therapeutics, 2010, advance online publication 27 January 2010, doi: 10.1038/clpt.2009.234 (Reference)

PENTA 15

Jacqz-Aigrain, Farrelly L, Compagnucci A, Harrison L, Zhao W, Hamadache D, Welch S, Wintergerst U, Firtion G, Burger D. PENTA 15: plasma pharmacokinetic study of once versus twice daily abacavir and lamivudine as part of combination antiretroviral therapy in HIV-1 infected children aged 3 to <36 months. CROI 2009. February 8-11, 2009. Palais des Congres de Montreal, Canada , Poster S-154.(Poster)

Zhao W, Farrelly L, Compagnucci A, Harrison L, Jacqz-Aigrain E, Hamadache D, Welch S, Wintergerst U, Burger D on behalf of the PENTA Trial Steering Committee .PENTA 15: Once-daily abacavir and lamivudine as part of combination antiretroviral therapy to 48 weeks in HIV-1 infected children aged 3 to 36 months. 1st International Workshop on HIV Pediatrics, 17 – 18 July 2009, Cape Town, South Africa (presentation)

PENTA. Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months. Antiviral Therapy, 2010;15(3):297-305. Reference.

General PENTA publications

Paediatric European Network for treatment of AIDS - a network for multicentre trials. The PENTA 1 trial. First European Paediatric Congress, Paris, France 9 - 12 March, 1994.

Paediatric European Network for treatment of AIDS (PENTA). Xth International Conference on AIDS, Yokohama, Japan 7 - 12 August,. 1994.

Paediatric European Network for treatment of AIDS (PENTA). 2nd International Congress on Drug Therapy in HIV Infection, Glasgow, UK 19-22 November, 1994.

Paediatric European Network for treatment of AIDS (PENTA). XIth International Conference on AIDS, Vancouver, Canada 7 - 12 July, 1996.

Bernardi S, Thorne C, Newell ML, Giaquinto C,Tovo PA, Rossi P. Variable use of therpaeutic interventions for children with human immunodeficiency virus type 1 infection in Europe. European Journal of Pediatrics 2000; 159(3):170-5 (Reference)

Sharland M, Gibb DM, Giaquinto C. Current evidence for the use of pediatric antiretroviral therapy - a PENTA analysis European Journal of Pediatrics 2000; 159:649-656. (Reference)

Sharland M, Castelli Gattinara G, Tomas Ramos J, Blanche S, Gibb DM for the PENTA Steering Committee. PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. HIV Med 2002; 3:215-226 (.pdf file)

HIV Paediatric Prognostic Markers Collaborative Study Group. Short-term risk of disease progression in HIV-1 infected children receiving no antiretroviral therapy or zidovudine monotherapy: estimates according to CD4 percent, viral load, and age. Lancet 2003; 362:1605-11. (Reference)

Sharland M, Blanche S, Castelli G, Ramos J, Gibb DM for the PENTA Steering Committee. PENTA guidelines for the use of antiretroviral therapy 2004. HIV Med 2004; 5, (Suppl. 2), 61-86 (.pdf file)

Urschel S, Ramos J, Mellado M, Giaquinto C, Verweel G, Schuster T, Niehues T, Belohradsky B, Wintergerst U; the European PCP-withdrawal Study Group. Withdrawal of Pneumocystis jirovecii prophylaxis in HIV-infected children under highly active antiretroviral therapy. AIDS. 2005 Dec 2;19(18):2103-2108. (Reference)

HIV Paediatric Prognostic Markers Collaborative Study Group. Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta-analysis of longitudinal data. Lancet 2005; 366: 1868-74 . (Reference)

HIV Paediatric Prognostic Markers Collaborative Study. Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS 2006; 20:1289-1294 (Reference)

Green H and Gibb DM. Treatment interruption in children with HIV infection. Curr Opin HIV AIDS 2007; 2:62-68.

Babiker AG and Gibb DM. Considerations in the design of randomized controlled trials evaluating the optimal time to initiate antiretroviral therapy in previously untreated HIV-1 infected patients. Current Opinion in HIV and AIDS 2006; 1(6):488-494 (Reference)

Dunn D, Woodburn P, Duong T, Phillips A, Gibb DM and Porter K on behalf of HPPMCS and CASCADE. A comparison of the association of current CD4 cell count with the short-term risk of AIDS and death in HIV-infected children and adults. 14th Conference on Retroviruses and Opportunistic Infections, 25th-28th February 2007, Los Angeles. Poster 700 (.pdf file)

PENTA has endorsed the policy statement: Increasing Antiretroviral Drug Access for Children With HIV Infection. American Academy of Pediatrics, 2007; 119: 838-845 (.pdf file)

Cross Continents Collaboration for Kids (3Cs4kids) Analysis and Writing Committee. Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis. AIDS. 2008 Jan 2;22(1):97-105. (Reference)

Goetghebuer T for the European Infant Collaborative Study. Early versus deferred highly active antiretroviral therapy in HIV infected infants: a European Collaborative Cohort Study. 4th Dominique Dormont International Conference, 13-15 December, 2007 (oral presentation).

Dunn DT, Woodburn P, Duong T, Phillips AN, Gibb D, Porter K on behalf of HIV Paediatric Prognostic Markers Collaborative Study (HPPMCS) and the CASCADE Collaboration. A comparison of the rate of clinical disease progression in HIV-infected children and adults allowing for current CD4 cell count. J Infect Dis 2008, 197:398-404 (Reference)

Goetghebuer T, Haelterman E, Le Chenadec J, Dollfus C, Gibb D, Judd A, Green H, Galli L, Ramos JT, Giaquinto C, Warszawski J, Levy J; for the European Infant Collaboration group. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS 2009 Feb (pre-pub reference)

PENTA: 2009 Guidelines for the use of Antiretroviral therapy. HIV Med. 2009 Nov;10(10):591-613.(reference) click here to view the pdf

Immunology

Gibb DM, Newberry A, Klein N, de Rossi A, Grosch-Woerner I, Babiker A. Immune repopulation after HAART in previously untreated HIV-1 infected children. see under PENTA 5

King D, Gibb DM, Gotch F, Larsson-Sciard E. Reconstitution of the T-cell Pool in Treated, HIV-infected Children. see under PENTA 5

Gibb DM. HIV-1 Viral Load and CD4 Count in Untreated Children with Vertically Acquired Mild or Asymptomatic Disease - PENTA I Virology. see under PENTA 1

King D J.S., Gotch F M. & Larsson-Sciard E. T cell repopulation in HIV infected children on highly active anti-retroviral therapy (HAART).see under PENTA 5

De Rossi A, Klein N, Walker AS, De Forni D, Babiker A, King D, Gibb DM for the PENTA Group. TREC Response to Antiretroviral Therapy in HIV-infected Children in the PENTA 5 Trial see under PENTA 5

De Rossi A, Walker AS, De Forni D, Gibb DM for PENTA. Biphasic decay of cell-associated HIV-1 DNA in HIV-1 infected children on antiretroviral therapy. See under PENTA 5

Jacobsen MC, Thiebaut R, Fisher C, Sefe D, Clapson M, Klein NJ, Baxendale HE. Marginal zone memory B-cell populations are irreversibly depleted in paediatric HIV infection. 15th Conference on Retroviruses and Opportunistic Infections, Boston, 2- 8 February 2008, Poster A-152 /453 (pdf file)

Resistance

Kaye. S., Loveday. C., Gibb. DM., Newberry. A. Plasma viral load and genotypic resistance patterns in children adding lamivudine to current reverse transcriptase inhibitor therapy (PENTA 4 Trial). see under PENTA 4

Kaye S. on behalf of the PENTA Virology Committee. Drug resistance in a trial of nucleoside-analogue and protease inhibitor therapy in children (PENTA 5). see under PENTA 5

Loveday. C., Walker. A.S., Gibb. D.M., on behalf of the PENTA virology Group. Evolution of drug resistance in antiretroviral therapy-naïve children in PENTA 5. See under PENTA 5

>Ait-Khaled M, Lanier R, Richards N, Stoen C, Griffin P, Gibb DM, Walker AS, Craig C, Loeliger E, Tisdale M. Zidovudine (ZDV) appears to prevent selection of K65R and L74V, mutations normally selected by Abacavir (ABC) mono- or combination therapies not containing ZDV. See under PENTA 5

Pharmacology

Compagnucci A, Saidi Y, Faye A, Ciria Calavia L, Gibb DM, Girard S, Quernin MH, Harper L, Giaquinto G, Debré M, Weigel R, Giacomet V, Aboulker JA, Jacqz-Aigrain E, Walker AS. Impact of NFV and its active metabolite M8 trough levels on virologic response from primary HIV-1 vertically infected children treated with d4T, ddI and NFV in the PENTA 7 study. see under PENTA 7

Cella M, Zhao W, Dann o M, Della Pasqua O: Extrapolating abacavir doses from children to babies and vice-versa: a case study. Pharmaceutical Translational Research Conference 2-3 April 2009 London. (poster)

Cella M, Gorter de Vries F, Burger D, Danhof M, Della Pasqua O. A Model-based approach to dose selection in early pediatric development. See under PENTA 13.

* acknowledges permission of the University of Chicago Press to reproduce the publication here

Only major publications and presentations at international meetings are listed. For a complete list of PENTA publications, please contact a Trials Centre.

PENTA publication policy

Updated 23 July, 2010